Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

Cell

Volumn 167, Issue 3, 2016, Pages 684-694.e9

  Gilchuk, Iuliia ^a   Gilchuk, Pavlo ^a,b   Sapparapu, Gopal ^a   Lampley, Rebecca ^a   Singh, Vidisha ^a   Kose, Nurgun ^a   Blum, David L ^a   Hughes, Laura J ^c   Satheshkumar, Panayampalli S ^c   Townsend, Michael B ^c   Kondas, Ashley V ^c   Reed, Zachary ^c   Weiner, Zachary ^c   Olson, Victoria A ^c   Hammarlund, Erika ^d   Raue, Hans Peter ^d   Slifka, Mark K ^d   Slaughter, James C ^a   Graham, Barney S ^e   Edwards, Kathryn M ^a   Eisenberg, Roselyn J ^f   Cohen, Gary H ^f   Joyce, Sebastian ^a,b   Crowe, James E ^a   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antigen specificity; cross neutralization; human monoclonal antibodies; poxvirus infections; protective immunity; smallpox vaccine

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VACCINIA ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD CELL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COWPOX VIRUS; CROSS REACTION; FEMALE; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; MALE; MONKEYPOX; MONKEYPOX VIRUS; MOUSE; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; SMALLPOX VIRUS; VACCINATION; VACCINIA; VIRION; VIRUS NEUTRALIZATION; COWPOX; IMMUNOLOGY; MONONUCLEAR CELL; SMALLPOX; VACCINIA VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; COWPOX; COWPOX VIRUS; CROSS REACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MONKEYPOX; MONKEYPOX VIRUS; POXVIRIDAE INFECTIONS; SMALLPOX; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 84992677658     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.09.049     Document Type: Article

References (44)

1. Amanna, I.J., Raué, H.P., Slifka, M.K., Development of a new hydrogen peroxide–based vaccine platform. Nat. Med. 18 (2012), 974–979.
2. Baxby, D., The surface antigens of orthopoxviruses detected by cross-neutralization tests on cross-absorbed antisera. J. Gen. Virol. 58 (1982), 251–262.
3. Bell, E., Shamim, M., Whitbeck, J.C., Sfyroera, G., Lambris, J.D., Isaacs, S.N., Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325 (2004), 425–431.
4. Belyakov, I.M., Earl, P., Dzutsev, A., Kuznetsov, V.A., Lemon, M., Wyatt, L.S., Snyder, J.T., Ahlers, J.D., Franchini, G., Moss, B., Berzofsky, J.A., Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100 (2003), 9458–9463.
5. Benhnia, M.R., McCausland, M.M., Su, H.P., Singh, K., Hoffmann, J., Davies, D.H., Felgner, P.L., Head, S., Sette, A., Garboczi, D.N., Crotty, S., Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 82 (2008), 3751–3768.
6. Benhnia, M.R., McCausland, M.M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koriazova, L., Kubo, R., Kato, S., Crotty, S., Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83 (2009), 1201–1215.
7. Bosma, M.J., Carroll, A.M., The SCID mouse mutant: definition, characterization, and potential uses. Annu. Rev. Immunol. 9 (1991), 323–350.
8. Chapman, J.L., Nichols, D.K., Martinez, M.J., Raymond, J.W., Animal models of orthopoxvirus infection. Vet. Pathol. 47 (2010), 852–870.
9. Crowe, J.E. Jr., Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 27:Suppl 6 (2009), G47–G51.
10. Davies, D.H., Liang, X., Hernandez, J.E., Randall, A., Hirst, S., Mu, Y., Romero, K.M., Nguyen, T.T., Kalantari-Dehaghi, M., Crotty, S., et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA 102 (2005), 547–552.
11. Davies, D.H., McCausland, M.M., Valdez, C., Huynh, D., Hernandez, J.E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P.L., Crotty, S., Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79 (2005), 11724–11733.
12. Davies, D.H., Molina, D.M., Wrammert, J., Miller, J., Hirst, S., Mu, Y., Pablo, J., Unal, B., Nakajima-Sasaki, R., Liang, X., et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7 (2007), 1678–1686.
13. Edghill-Smith, Y., Golding, H., Manischewitz, J., King, L.R., Scott, D., Bray, M., Nalca, A., Hooper, J.W., Whitehouse, C.A., Schmitz, J.E., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11 (2005), 740–747.
14. Flexner, C., Hügin, A., Moss, B., Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330 (1987), 259–262.
15. Hammarlund, E., Lewis, M.W., Carter, S.V., Amanna, I., Hansen, S.G., Strelow, L.I., Wong, S.W., Yoshihara, P., Hanifin, J.M., Slifka, M.K., Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 11 (2005), 1005–1011.
16. Hughes, A.L., Irausquin, S., Friedman, R., The evolutionary biology of poxviruses. Infect. Genet. Evol. 10 (2010), 50–59.
17. Hughes, C.M., Newman, F.K., Davidson, W.B., Olson, V.A., Smith, S.K., Holman, R.C., Yan, L., Frey, S.E., Belshe, R.B., Karem, K.L., Damon, I.K., Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines. Clin. Vaccine Immunol. 19 (2012), 1116–1118.
18. Ichihashi, Y., Oie, M., Epitope mosaic on the surface proteins of orthopoxviruses. Virology 163 (1988), 133–144.
19. Kempe, C.H., Bowles, C., Meiklejohn, G., Berge, T.O., St Vincent, L., Babu, B.V., Govindarajan, S., Ratnakannan, N.R., Downie, A.W., Murthy, V.R., The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull. World Health Organ. 25 (1961), 41–48.
20. Kemper, A.R., Davis, M.M., Freed, G.L., Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5 (2002), 84–90.
21. Kennedy, J.S., Gurwith, M., Dekker, C.L., Frey, S.E., Edwards, K.M., Kenner, J., Lock, M., Empig, C., Morikawa, S., Saijo, M., et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J. Infect. Dis. 204 (2011), 1395–1402.
22. Lantto, J., Haahr Hansen, M., Rasmussen, S.K., Steinaa, L., Poulsen, T.R., Duggan, J., Dennis, M., Naylor, I., Easterbrook, L., Bregenholt, S., et al. Capturing the natural diversity of the human antibody response against vaccinia virus. J. Virol. 85 (2011), 1820–1833.
23. Lewis, M.W., Graham, M.B., Hammarlund, E., Hanifin, J., Slifka, M.K., Monkeypox without exanthem. N. Engl. J. Med. 356 (2007), 2112–2114.
24. Lustig, S., Fogg, C., Whitbeck, J.C., Eisenberg, R.J., Cohen, G.H., Moss, B., Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79 (2005), 13454–13462.
25. Mack, T.M., Noble, J. Jr., Thomas, D.B., A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21 (1972), 214–218.
26. Matho, M.H., Maybeno, M., Benhnia, M.R., Becker, D., Meng, X., Xiang, Y., Crotty, S., Peters, B., Zajonc, D.M., Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5. J. Virol. 86 (2012), 8050–8058.
27. McCausland, M.M., Benhnia, M.R., Crickard, L., Laudenslager, J., Granger, S.W., Tahara, T., Kubo, R., Koriazova, L., Kato, S., Crotty, S., Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. (Lond.) 15 (2010), 661–675.
28. McCollum, A.M., Nakazawa, Y., Ndongala, G.M., Pukuta, E., Karhemere, S., Lushima, R.S., Ilunga, B.K., Kabamba, J., Wilkins, K., Gao, J., et al. Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. Am. J. Trop. Med. Hyg. 93 (2015), 718–721.
29. McConnell, S., Herman, Y.F., Mattson, D.E., Huxsoll, D.L., Lang, C.M., Yager, R.H., Protection of Rhesus Monkeys against Monkeypox by Vaccinia Virus Immunization. Am. J. Vet. Res. 25 (1964), 192–195.
30. Moss, B., Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239 (2011), 8–26.
31. Reed, K.D., Melski, J.W., Graham, M.B., Regnery, R.L., Sotir, M.J., Wegner, M.V., Kazmierczak, J.J., Stratman, E.J., Li, Y., Fairley, J.A., et al. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350 (2004), 342–350.
32. Ruiz, M., Giudicelli, V., Ginestoux, C., Stoehr, P., Robinson, J., Bodmer, J., Marsh, S.G., Bontrop, R., Lemaitre, M., Lefranc, G., et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 28 (2000), 219–221.
33. Smith, G.L., McFadden, G., Smallpox: anything to declare?. Nat. Rev. Immunol. 2 (2002), 521–527.
34. Smith, S.A., Zhou, Y., Olivarez, N.P., Broadwater, A.H., de Silva, A.M., Crowe, J.E. Jr., Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol. 86 (2012), 2665–2675.
35. Smith, S.A., de Alwis, A.R., Kose, N., Jadi, R.S., de Silva, A.M., Crowe, J.E. Jr., Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 88 (2014), 12233–12241.
36. Stanford, M.M., McFadden, G., Karupiah, G., Chaudhri, G., Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. 85 (2007), 93–102.
37. Thornburg, N.J., Nannemann, D.P., Blum, D.L., Belser, J.A., Tumpey, T.M., Deshpande, S., Fritz, G.A., Sapparapu, G., Krause, J.C., Lee, J.H., et al. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J. Clin. Invest. 123 (2013), 4405–4409.
38. Verardi, P.H., Titong, A., Hagen, C.J., A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum. Vaccin. Immunother. 8 (2012), 961–970.
39. Vorou, R.M., Papavassiliou, V.G., Pierroutsakos, I.N., Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21 (2008), 153–156.
40. Weitkamp, J.H., Kallewaard, N., Kusuhara, K., Feigelstock, D., Feng, N., Greenberg, H.B., Crowe, J.E. Jr., Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J. Immunol. Methods 275 (2003), 223–237.
41. Wittek, R., Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 10 (2006), 193–201.
42. Wyatt, L.S., Earl, P.L., Eller, L.A., Moss, B., Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101 (2004), 4590–4595.
43. Yu, X., McGraw, P.A., House, F.S., Crowe, J.E. Jr., An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J. Immunol. Methods 336 (2008), 142–151.
44. Zaitseva, M., Kapnick, S.M., Meseda, C.A., Shotwell, E., King, L.R., Manischewitz, J., Scott, J., Kodihalli, S., Merchlinsky, M., Nielsen, H., et al. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J. Virol. 85 (2011), 9147–9158.